{
  "drug_name": "Prulifloxacin",
  "tradename": "Quisnon, Sword, Pruquin, Unidrox",
  "usage_and_dosing": {
    "general": [
      "Prulifloxacin is a fluoroquinolone marketed in several countries, but not approved in the US.",
      "Prulifloxacin is a lipophilic oral prodrug of Ulifloxacin.",
      "Originally developed in Japan and marketed there under the trade names Quisnon and Sword. Also available in Europe. Pruquin and Unidrox are among other trade names.",
      "Only available as oral formulation.",
      "Approved in Italy and Japan for:",
      "Acute uncomplicated lower urinary tract infections (cystitis)",
      "Complicated lower urinary tract infections",
      "Acute exacerbations of chronic bronchitis",
      "Japan: Infectious Diarrhea, e.g., traveler's diarrhea",
      "Spectrum of in vitro activity similar to Ciprofloxacin.",
      "Long half-life allows once daily dosing.",
      "See Fluoroquinolones, Overview for class-wide issues, including usage, resistance mechanisms, adverse effects, pharmacology."
    ],
    "adult_dose": {
      "note": "Dose by indication (see Comments):",
      "acute_uncomplicated_cystitis": "600 mg po (single dose)",
      "complicated_lower_utis": "600 mg po q24h for up to 10 days",
      "acute_exacerbations_of_chronic_bronchitis": "600 mg po q24h for up to 10 days"
    },
    "pediatric_dose": {
      "dose_age_gt_28_days": "Safety and efficacy not established",
      "max_day": "-"
    }
  },
  "renal_adjustment": {
    "half_life_normal": "10.6-12.1",
    "half_life_esrd": "No data",
    "dose_renal_function_normal": "600 mg po q24h",
    "crcl_or_egfr": "CrCl ≥60: No dosage adjustment. CrCl <60: No data",
    "hemodialysis": "No data",
    "capd": "No data",
    "crrt": "No data",
    "sled": "No data"
  },
  "hepatic_adjustment": {
    "mild_impairment_child_pugh_a": "No dosage adjustment",
    "moderate_impairment_child_pugh_b": "No dosage adjustment",
    "severe_impairment_child_pugh_c": "No dosage adjustment"
  },
  "adverse_effects": {
      "contraindications": [
          "Persons with celiac disease",
          "Do not use in children, pregnancy, nursing mothers, and patients with a seizure disorder."
      ],
      "class_wide_adverse_effects": "For class-wide adverse effects, see Fluoroquinolones, Overview.",
      "drug_interactions": "Many drug-drug interactions, see below",
      "qtc_prolongation": "Interaction with concomitant drugs may increase the risk of prolongation of the QTc.",
      "lactose": "Marketed formulation contains lactose."
  },
  "antimicrobial_spectrum": {
    "preferred": [
        "Francisella tularensis",
        "Haemophilus ducreyi",
        "Klebsiella granulomatis (granuloma inguinale)",
        "Legionella sp.",
        "Yersinia enterocolitica"
    ],
    "alternative": []
  },
  "pharmacology": {
    "pk_pd_index": "24-hr AUC/MIC",
    "preparations": "Tab (600 mg)",
    "food_recommendation": "Tab ± food",
    "oral_absorption_percent": "No data",
    "tmax_hr": "1",
    "peak_serum_conc_ug_ml": "Ulifloxacin 1.6 (600 mg po, SD)",
    "peak_urine_conc_ug_ml": "No data",
    "protein_binding_percent": "45",
    "volume_of_distribution_vd_l": "1231 L",
    "avg_serum_half_life_hr": "10.6-12.1",
    "elimination": "Fecal",
    "bile_penetration_percent": "No data",
    "csf_blood_percent": "Negligible",
    "therapeutic_levels_in_csf": "No",
    "auc_ug_hr_ml": "7.3 (600 mg po, 0-inf)"
  },
  "major_drug_interactions": [
      {"drug": "Antacids (Al, Mg)", "effect": "↓ prulifloxacin", "management": "Give prulifloxacin 2 hr before after"},
      {"drug": "Calcium supplements", "effect": "↓ prulifloxacin", "management": "Give prulifloxacin 2 hr before after"},
      {"drug": "Cimetidine", "effect": "↓ prulifloxacin", "management": "Give prulifloxacin 2 hr before after"},
      {"drug": "Didanosine", "effect": "↓ prulifloxacin", "management": "Give prulifloxacin 2 hr before after"},
      {"drug": "Insulin", "effect": "↑↓ blood glucose", "management": "Monitor"},
      {"drug": "Iron supplements", "effect": "↓ prulifloxacin", "management": "Give prulifloxacin 2 hr before after"},
      {"drug": "Nicardipine", "effect": "↑ risk of prulifloxacin phototoxicity", "management": "Monitor or avoid"},
      {"drug": "NSAIDS", "effect": "↑ risk of CNS stimulation/seizures", "management": "Monitor or avoid"},
      {"drug": "Oral hypoglycemics", "effect": "↑↓ blood glucose", "management": "Monitor"},
      {"drug": "Sucralfate", "effect": "↓ prulifloxacin", "management": "Give prulifloxacin 2 hr before after"},
      {"drug": "Theophylline", "effect": "↑ theophylline", "management": "Monitor or avoid"},
      {"drug": "Warfarin", "effect": "↑ warfarin, ↑ INR", "management": "Monitor INR, adjust dosa"},
      {"drug": "Zinc", "effect": "↓ prulifloxacin", "management": "Give prulifloxacin 2 hr before after"}
  ],
  "comments": [
      "References: Drugs 64:2221, 2004; Int J Antimicrob Agts 37:283, 2011.",
      "Spectrum and traveler's diarrhea pathogen susceptibility: Antimicrob Agents Chemother 53:1221,2009."
  ]
}
